Home Home Home Inbox Home Search

Event

Lung Function and Patient-Reported Outcomes Response to Glycopyrrolate (SEEBRI™ Neohaler®) in Chronic Obstructive Pulmonary Disease (COPD) Patients by Reversibility: Pooled Analysis of the GEM1 and GEM2 Studies [Board No. P462]

Location: Board no. P462
Session Type: Thematic Poster Session
Sunday
May
20
11:15 AM
1:00 PM

Speaker(s)/Author(s)

Jill A. Ohar

MD
Wake Forest Univ Sch of Med;Wake Forest Univ Sch of Medicine;Wake Forest University School of Medicine

Thomas Goodin

PhD
Sunovion Pharmaceuticals Inc.

Ayca Ozol-Godfrey

PhD
Sunovion Pharmaceuticals Inc.

Shahin Sanjar

PhD/ScD Doctoral Equivalent
Sunovion Pharmaceuticals Inc.

Sanjay Sharma

Bachelors Degree
Sunovion Pharmaceuticals Inc.

Barry Price

RRT, MBA
Sunovion Pharmaceuticals Inc.

Alyssa Bowling

Other Healthcare Related Doctorate (PharmD)
Sunovion Pharmaceuticals Inc.

View Abstract

Lung Function and Patient-Reported Outcomes Response to Glycopyrrolate (SEEBRI™ Neohaler®) in Chronic Obstructive Pulmonary Disease (COPD) Patients by Reversibility: Pooled Analysis of the GEM1 and GEM2 Studies

Parent Sessions

  • A75 - COPD: TARGETS, MODELS, AND CLINICAL STUDIES...
    05-20-2018 9:15 AM - 4:15 PM
    • Home Home Home Inbox Home Search